Racemic synthesis of carbocyclic purine nucleoside analogues with restricted glycosyl conformation

Abstract

Carbocyclic purine nucleoside analogues which have restricted glycosyl conformation at χ ≈ 180° were designed, based on the conformational features of the L-nucleotide residue in heterochiral DNA, and synthesized. The synthesis of (±)-carbocyclic 8,6′-O-anhydro-8,6′-dihydroxy-2′-deoxyadenosine 3 was achieved by intramolecular cyclization of the 8-bromo-6′-O-tosyl-2′-deoxyadenosine derivative. (±)-Carbocyclic 8,6′-O-anhydro-8,6′-dihydroxy-2′-deoxyguanosine 4 was synthesized from the carbocyclic 2,6-diaminopurine nucleoside derivative via the carbocyclic 8-bromo-6′-O-mesyl-2′-deoxyguanosine derivative.

References

1. (a) For a review on the chemistry and biology of nucleosides, see: Nucleosides as Biological Probes, ed. R. J. Suhadolnik, John Wiley & Sons, New York, 1979; (b) Nucleosides and Nucleotides as Antitumor and Antiviral Agents, ed. C. K. Chu and D. C. Baker, Plenum Press, New York, 1993; (c) Antiviral Drug Development, ed. E. De Clercq and R. T. Walker, Plenum Press; New York, 1988.
2. E. Dias, J. L. Battiste and J. R. Williamson, J. Am. Chem. Soc., 1994, 116, 4479.
3. (a) V. E. Marquez, A. Ezzitouni, P. Russ, M. A. Siddiqui, H. Ford, Jr., R. J. Feldman, H. Mitsuya, C. George and J. J. Barchi, Jr., J. Am. Chem. Soc., 1998, 120, 2780; (b) C. W. Lin, M. Hanna and J. W. Szostack, Biochemistry, 1994, 33, 2703.
4. (a) S. S. Tavale and H. M. Sobell, J. Mol. Biol., 1970, 48, 109; (b) M. Ikehara, S. Uesugi and K. Yoshida, Biochemistry, 1972, 11, 830.
5. M. A. Abdallah, J. F. Biellmann, B. Nordstrom and C.-I. Branden, Eur. J. Biochem., 1975, 50, 475.
6. H. Urata, Y. Ueda, H. Suhara, E. Nishioka and M. Akagi, J. Am. Chem. Soc., 1993, 115, 9852.
7. H. Urata and M. Akagi, Tetrahedron Lett., 1996, 37, 5551.
8. (a) R. E. Dickerson and H. R. Drew, J. Mol. Biol., 1981, 149, 761; (b) H. R. Drew, R. M. Wing, T. Takano, C. Broka, S. Tanaka, K. Itakura and R. E. Dickerson, Proc. Natl. Acad. Sci. U.S.A., 1981, 78, 2179.
9. (a) T. Maruyama, S. Sato and M. Honjo, Chem. Pharm. Bull., 1982, 30, 2688; (b) T. Ueda and S. Shuto, Nucleosides, Nucleotides, 1984, 3, 173; (c) M. Ikehara and M. Kaneko, Chem. Pharm. Bull., 1967, 15, 1261.
10. (a) N. Miller and J. J. Fox, J. Org. Chem., 1964, 29, 1772; (b) D. A. Schuman, M. J. Robins and R. K. Robins, J. Am. Chem. Soc., 1970, 92, 3434; (c) M. Clark, A. Todd and J. Zussman, J. Chem. Soc., 1951, 2952; (d) Y. Yoshimura, B. A. Otter, T. Ueda and A. Matsuda, Chem. Pharm. Bull., 1992, 40, 1761; (e) S. G. Zavgorodony, Tetrahedron, 1981, 22, 3003.
11. H. Urata, H. Miyagoshi, H. Kakuya, H. Tokumoto, T. Kawahata, T. Otake and M. Akagi, Chem. Pharm. Bull., 1998, 46, 458.
12. H. Ohishi, H. Urata, M. Akagi and K. Tomita, Acta Crystallogr., Sect. C, 1998, 54, 980.
13. A. D. Borthwick and K. Biggadike, Tetrahedron, 1992, 48, 571.
14. (a) K. Biggadike, A. D. Borthwick, D. Evans, A. M. Exall, B. E. Kirk, S. M. Roberts, L. Stephenson and P. Youds, J. Chem. Soc., Perkin Trans. 1, 1988, 549; (b) J. J. Partridge, N. K. Chadha and M. R. Uskokovic, J. Am. Chem. Soc., 1973, 95, 532.
15. (a) M. Ikehara and T. Maruyama, Tetrahedron, 1975, 31, 1369; (b) M. Ikehara and M. Kaneko, Chem. Pharm. Bull., 1970, 18, 2401.
16. (a) M. F. Jones, P. L. Myers, C. A. Robertson, R. Storer and C. Williamson, J. Chem. Soc., Perkin Trans. 1, 1991, 2479; (b) P. Herdewijn, J. Balzarini, M. Baba, R. Pauwels, A. V. Aerschot, G. Janssen and E. De Clercq, J. Med. Chem., 1988, 31, 2040.